Orai3-mediated SOCE in ER+ breast cancer cells has been shown to be modulated by the TRP channel, TRPC6, as TRPC6 knockdown or transient expression of a dominant negative TRPC6 mutant resulted in attenuation of the plasma membrane expression of Orai3 and well as SOCE inhibition in MCF7 cells [35]. Here, ORAI3 is linked to breast carcinoma.